JP2005500389A5 - - Google Patents

Download PDF

Info

Publication number
JP2005500389A5
JP2005500389A5 JP2003521776A JP2003521776A JP2005500389A5 JP 2005500389 A5 JP2005500389 A5 JP 2005500389A5 JP 2003521776 A JP2003521776 A JP 2003521776A JP 2003521776 A JP2003521776 A JP 2003521776A JP 2005500389 A5 JP2005500389 A5 JP 2005500389A5
Authority
JP
Japan
Prior art keywords
antibody
pharmaceutical composition
disease
soluble
affinity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003521776A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005500389A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2002/021324 external-priority patent/WO2003016467A2/en
Publication of JP2005500389A publication Critical patent/JP2005500389A/ja
Publication of JP2005500389A5 publication Critical patent/JP2005500389A5/ja
Pending legal-status Critical Current

Links

JP2003521776A 2001-08-17 2002-08-14 Aβに関連する病態および疾患を治療するための、可溶性Aβに高い親和性を有する抗体の使用 Pending JP2005500389A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US31357601P 2001-08-17 2001-08-17
US38385102P 2002-05-28 2002-05-28
PCT/US2002/021324 WO2003016467A2 (en) 2001-08-17 2002-08-14 Use of antibodies having high affinity for soluble ass to treat conditions and diseases related to ass

Publications (2)

Publication Number Publication Date
JP2005500389A JP2005500389A (ja) 2005-01-06
JP2005500389A5 true JP2005500389A5 (https=) 2006-01-05

Family

ID=26978953

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003521776A Pending JP2005500389A (ja) 2001-08-17 2002-08-14 Aβに関連する病態および疾患を治療するための、可溶性Aβに高い親和性を有する抗体の使用

Country Status (5)

Country Link
US (1) US20040241164A1 (https=)
EP (1) EP1429805A4 (https=)
JP (1) JP2005500389A (https=)
CA (1) CA2452104A1 (https=)
WO (1) WO2003016467A2 (https=)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7588766B1 (en) 2000-05-26 2009-09-15 Elan Pharma International Limited Treatment of amyloidogenic disease
US6761888B1 (en) 2000-05-26 2004-07-13 Neuralab Limited Passive immunization treatment of Alzheimer's disease
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US7179892B2 (en) * 2000-12-06 2007-02-20 Neuralab Limited Humanized antibodies that recognize beta amyloid peptide
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US7790856B2 (en) 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US7700751B2 (en) 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
TWI255272B (en) 2000-12-06 2006-05-21 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US20060073149A1 (en) * 2001-08-17 2006-04-06 Bales Kelly R Rapid improvement of cognition in condition related to abeta
JP2005503789A (ja) * 2001-08-17 2005-02-10 イーライ・リリー・アンド・カンパニー 抗Aβ抗体
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
MXPA05003621A (es) * 2002-10-09 2005-10-19 Rinat Neuroscience Corp Metodos de tratamiento de la enfermedad de alzheimer usando anticuerpos dirigidos contra el peptido beta amiloide y composiciones de los mismos.
DE10303974A1 (de) * 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
DE602004027348D1 (de) 2003-02-10 2010-07-08 Applied Molecular Evolution Abeta-bindende moleküle
EP1613657A2 (en) * 2003-03-28 2006-01-11 Centocor, Inc. Anti-amyloid antibodies, compositions, methods and uses
PE20050627A1 (es) 2003-05-30 2005-08-10 Wyeth Corp Anticuerpos humanizados que reconocen el peptido beta amiloideo
DE602005022871D1 (de) * 2004-06-07 2010-09-23 Univ Ramot Verfahren zur passiven immunisierung gegen eine durch amyloidaggregation gekennzeichnete krankheit oder erkrankung mit vermindertem nervenentzündungsrisiko
BRPI0513959A (pt) 2004-07-30 2008-05-20 Rinat Neuroscience Corp anticorpos dirigidos contra o peptìdeo beta-amilóide, suas composições farmacêuticas, kit e métodos de fabricação dos mesmos
EP1838349A1 (en) * 2004-12-15 2007-10-03 Neuralab, Ltd. Amyloid beta antibodies for use in improving cognition
TW200636066A (en) 2004-12-15 2006-10-16 Elan Pharm Inc Humanized antibodies that recognize beta amyloid peptide
WO2006066089A1 (en) * 2004-12-15 2006-06-22 Neuralab Limited Humanized amyloid beta antibodies for use in improving cognition
US7906625B2 (en) 2005-01-24 2011-03-15 Amgen Inc. Humanized anti-amyloid antibody
PE20061323A1 (es) 2005-04-29 2007-02-09 Rinat Neuroscience Corp Anticuerpos dirigidos contra el peptido amiloide beta y metodos que utilizan los mismos
PL2289909T3 (pl) 2005-11-30 2015-04-30 Abbvie Inc Sposób przeszukiwania, proces oczyszczania niedyfundujących oligomerów Abeta, selektywne przeciwciała przeciw niedyfundującym oligomerom Abeta i sposób wytwarzania tych przeciwciał
RU2432362C2 (ru) 2005-11-30 2011-10-27 Эбботт Лэборетриз Моноклональные антитела и их применения
SG10201404801YA (en) 2005-12-12 2014-09-26 Ac Immune Sa Monoclonal antibody
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
NZ574188A (en) 2006-07-14 2012-05-25 Ac Immune Sa Humanized antibody against amyloid beta
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
PT2121754E (pt) * 2007-01-18 2015-05-11 Lilly Co Eli Fab de beta-amilóide peguilado
CA2676715A1 (en) 2007-02-12 2008-08-21 Merck & Co., Inc. Piperazine derivatives for treatment of ad and related conditions
EP2124952A2 (en) 2007-02-27 2009-12-02 Abbott GmbH & Co. KG Method for the treatment of amyloidoses
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
US8613923B2 (en) * 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
US8048420B2 (en) 2007-06-12 2011-11-01 Ac Immune S.A. Monoclonal antibody
PL2170389T3 (pl) * 2007-06-12 2015-03-31 Ac Immune Sa Humanizowane przeciwciało przeciw amyloidowi beta
PT2182983E (pt) 2007-07-27 2014-09-01 Janssen Alzheimer Immunotherap Tratamento de doenças amiloidogénicas com anticorpos anti-abeta humanizados
RS53174B (sr) 2007-10-05 2014-06-30 Genentech Inc. Upotreba antiamiloidnog beta antitela u slučaju oboljenja oka
JO3076B1 (ar) * 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
WO2009085200A2 (en) * 2007-12-21 2009-07-09 Amgen Inc. Anti-amyloid antibodies and uses thereof
WO2009104736A1 (ja) * 2008-02-22 2009-08-27 財団法人ヒューマンサイエンス振興財団 組織アミロイドプラーク親和性抗体及びそれを用いた医薬組成物
EP2320942B1 (en) 2008-07-21 2018-03-14 Probiodrug AG Diagnostic antibody assay
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
SI2453923T1 (sl) 2009-07-14 2016-04-29 Mayo Foundation For Medical Education And Research S peptidi posredovana ne-kovalentna dostava aktivnih učinkovin preko krvno možganske bariere
ES2684475T3 (es) 2010-04-15 2018-10-03 Abbvie Inc. Proteínas que se unen a beta amiloide
RU2607368C2 (ru) 2010-07-30 2017-01-10 Ац Иммуне С.А. Безопасные и функциональные гуманизированные антитела
CN103298833B (zh) 2010-08-14 2015-12-16 Abbvie公司 β淀粉样蛋白结合蛋白
JP2012233002A (ja) * 2012-08-03 2012-11-29 Janssen Alzheimer Immunotherapy 認知の改善における使用のためのアミロイドβ抗体
WO2014189973A2 (en) 2013-05-20 2014-11-27 Genentech, Inc. Anti-transferrin receptor antibodies and methods of use
US9896772B2 (en) * 2014-03-13 2018-02-20 Innosense Llc Modular chemiresistive sensor
US12345680B1 (en) 2014-03-13 2025-07-01 Innosense Corporation Modular chemiresistive sensor for real-time ethylene monitoring
EP3221361B1 (en) 2014-11-19 2021-04-21 Genentech, Inc. Anti-transferrin receptor / anti-bace1 multispecific antibodies and methods of use
EP3221362B1 (en) 2014-11-19 2019-07-24 F.Hoffmann-La Roche Ag Anti-transferrin receptor antibodies and methods of use
RU2017120039A (ru) 2014-12-10 2019-01-10 Дженентек, Инк. Антитела к рецепторам гематоэнцефалического барьера и способы их применения
US10072065B2 (en) 2015-08-24 2018-09-11 Mayo Foundation For Medical Education And Research Peptide-mediated delivery of immunoglobulins across the blood-brain barrier
US12311035B2 (en) 2018-10-04 2025-05-27 University Of Rochester Glymphatic delivery by manipulating plasma osmolarity
AR117453A1 (es) 2018-12-20 2021-08-04 Genentech Inc Fc de anticuerpos modificados y métodos para utilizarlas
WO2025250457A1 (en) 2024-05-28 2025-12-04 University Of Rochester Enhanced brain transduction by gene therapeutics

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5766846A (en) * 1992-07-10 1998-06-16 Athena Neurosciences Methods of screening for compounds which inhibit soluble β-amyloid peptide production
US5837672A (en) * 1992-07-10 1998-11-17 Athena Neurosciences, Inc. Methods and compositions for the detection of soluble β-amyloid peptide
US6114133A (en) * 1994-11-14 2000-09-05 Elan Pharmaceuticals, Inc. Methods for aiding in the diagnosis of Alzheimer's disease by measuring amyloid-β peptide (x-≧41)
TWI239847B (en) * 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US7964192B1 (en) * 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
BRPI0108676B8 (pt) * 2000-02-24 2021-05-25 Lilly Co Eli anticorpos humanizados que sequestram peptídeo amilóide beta e seus usos no tratamento de condições caracterizadas por formação de placas amiloides, bem como composição farmacêutica que compreende os referidos anticorpos
TWI255272B (en) * 2000-12-06 2006-05-21 Guriq Basi Humanized antibodies that recognize beta amyloid peptide

Similar Documents

Publication Publication Date Title
JP2005500389A5 (https=)
Alexopoulos Vascular disease, depression, and dementia.
Yamada et al. Animal models of Alzheimer's disease and evaluation of anti-dementia drugs
Kepe et al. PET imaging of neuropathology in tauopathies: progressive supranuclear palsy
WO2007068411A3 (en) Therapeutic vaccine
WO2003015691A3 (en) RAPID IMPROVEMENT OF COGNITION IN CONDITIONS RELATED TO A$g(b)
Fymat On dementia and other cognitive disorders
EA200501560A1 (ru) Предотвращение и терапия амилоидогенной болезни
WO2005014041A3 (en) Use of an amyloid beta dna vaccine for the treatment and/or prevention of amyloid diseases
JP2011504474A5 (https=)
RU2017103446A (ru) УЛУЧШЕННЫЕ АНТИТЕЛА, СВЯЗЫВАЮЩИЕ Аβ-ПРОТОФИБРИЛЛЫ
WO2003040183A3 (en) Compounds for the diagnosis/prevention/treatment of alzheimer's disease
Meador et al. Behavioral and cognitive effects of lamotrigine
WO2021139874A1 (en) Cognitive disorder prevention and therapy
Johansson et al. [11C]-PIB imaging in patients with Parkinson's disease: preliminary results
JP2009505979A5 (https=)
JP2013538186A (ja) 活性化増強型抗体の効果を増大させる方法
Zhang et al. Decreased nocturnal heart rate variability and potentially related brain regions in arteriosclerotic cerebral small vessel disease
Colding‐Jørgensen et al. Visual impairment in anti‐GQ1b positive Miller Fisher syndrome
Saletu et al. Propentofylline in adult-onset cognitive disorders: double-blind, placebo-controlled, clinical, psychometric and brain mapping studies
Holler et al. Camptocormia in Idiopathic Parkinson’s Disease:[[sup 123] I] β-CIT SPECT and Clinical Characteristics.
US5387614A (en) Use of sigma receptor ligands as salivary gland stimulants
Urban et al. Dysarthria-clumsy hand syndrome due to infarction of the cerebral peduncle
Agarwal et al. Wernekink commissure syndrome with bilateral cerebellar signs and holmes tremor in a patient with a preexisting movement disorder
Santhanam et al. Childhood polyarteritis nodosa presenting as central nervous system vasculitis